Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017

Hairong He, Qingqing Liu, Ning Li, Liyang Guo, Fengjie Gao, Ling Bai, Fan Gao, Jun Lyu, Hairong He, Qingqing Liu, Ning Li, Liyang Guo, Fengjie Gao, Ling Bai, Fan Gao, Jun Lyu

Abstract

Aim: Schizophrenia is a serious health problem worldwide. This systematic analysis aims to quantify the burden of schizophrenia at the global, regional and national levels using the Global Burden of Disease Study 2017 (GBD 2017).

Methods: We collected detailed information on the number of incidence cases, disability-adjusted life years (DALYs) and age-standardised incidence rate (ASIR) and age-standardised rate of DALYs (ASDR) during 1990-2017 from GBD 2017. The estimated annual percentage changes (EAPCs) in the ASIR and in the ASDR were calculated to quantify the temporal trends in the ASIR and ASDR of schizophrenia.

Results: Globally there were 1.13 million (95% uncertainty interval [UI] = 1.00 to 1.28) incident schizophrenia cases and 12.66 million (95% UI = 9.48 to 15.56) DALYs due to schizophrenia in 2017. The global ASIR decreased slightly from 1990 to 2017 (EAPC = -0.124, 95% UI = -0.114 to -0.135), while the ASDR was stable. The number of incident cases, DALYs, ASIR and ASDR were higher for males than for females. The incident rate and DALYs rate were highest among those aged 20-29 and 30-54 years, respectively. ASIR and ASDR were highest in East Asia in 2017, at 19.66 (95% UI = 17.72 to 22.00) and 205.23 (95% UI = 153.13 to 253.34), respectively. In 2017, the ASIR was highest in countries with a high-moderate sociodemographic index (SDI) and the ASDR was highest in high-SDI countries. We also found that the EAPC in ASDR was negatively correlated with the ASDR in 1990 (P = 0.001, ρ = -0.23).

Conclusion: The global burden of schizophrenia remains large and continues to increase, thereby increasing the burden on health-care systems. The reported findings should be useful for resource allocation and health services planning for the increasing numbers of patients with schizophrenia in ageing societies.

Keywords: DALYs; incidence; schizophrenia.

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Fig. 1.
Fig. 1.
The incident rate (a) and DALYs rate (b) of schizophrenia of different age group globally. DALYs, disability-adjusted life years.
Fig. 2.
Fig. 2.
The global disease burden of schizophrenia in 195 countries or territories. (a) The ASIR of schizophrenia in 2017. (b) The relative change in incident cases of schizophrenia between 1990 and 2017. (c) The EAPC of ASIR of schizophrenia from 1990 to 2017. Countries with an extreme number of cases/evolution were annotated. ASIR, age-standardised incident rate; EAPC, estimated annual percentage change.
Fig. 3.
Fig. 3.
The incident cases and DALYs of schizophrenia at a regional level. The left column in each group is case data in 1990 and the right column in 2017. DALYs, disability-adjusted life years.
Fig. 4.
Fig. 4.
ASIR (a) and ASDR (b) for schizophrenia by SDI, 1990–2017, and expected value-based SDI. The black line represents the average expected relationship between SDI and incidence (a) or DALYs (b) for schizophrenia based on values from all countries over the 1990–2017 estimation period. ASIR, age-standardised incident rate; ASDR, age-standardised rate of DALYs; SDI, sociodemographic index; DALYs, disability-adjusted life-years.
Fig. 5.
Fig. 5.
The incident cases (a), ASIR (b), DALYs number (c) and ASDR (d) for schizophrenia from 1990 to 2017 at SDI quintiles level. ASIR, age-standardised incident rate; ASDR, age-standardised rate of DALYs; DALYs, disability-adjusted life-years; SDI, sociodemographic index.
Fig. 6.
Fig. 6.
The correlation between EAPC of ASIR and ASIR in 1990 (a); EAPC of ASIR and HDI in 2017 (b); EAPC of ASDR and ASDR in 1990 (c); EAPC of ASDR and HDI in 2017 (d) of 195 countries or territories. The size of the circle represents the number of cases in this country in 2017. ASIR, age-standardised incident rate; ASDR, age-standardised rate of DALYs; EAPC, estimated annual percentage change; HDI, human development index; DALYs, disability-adjusted life years.

References

    1. Barnett R (2018) Schizophrenia. Lancet 391, 648.
    1. Chan S, Chan S, Pang HH, Yan KK, Hui C, Chang WC, Lee E and Chen E (2018) Association of an early intervention service for psychosis with suicide rate among patients with first-episode schizophrenia-spectrum disorders. JAMA Psychiatry 75, 458–464.
    1. Colodro-Conde L, Couvy-Duchesne B, Whitfield JB, Streit F, Gordon S, Kemper KE, Yengo L, Zheng Z, Trzaskowski M, de Zeeuw EL, Nivard MG, Das M, Neale RE, MacGregor S, Olsen CM, Whiteman DC, Boomsma DI, Yang J, Rietschel M, McGrath JJ, Medland SE and Martin NG (2018) Association between population density and genetic risk for schizophrenia. JAMA Psychiatry 75, 901–910.
    1. Cui X, Liu J and Luo X (2017) First-episode schizophrenia and diabetes risk. JAMA Psychiatry 74, 762–763.
    1. Dixon L (2017) What it will take to make coordinated specialty care available to anyone experiencing early schizophrenia: getting over the hump. JAMA Psychiatry 74, 7–8.
    1. Druss BG (2018) Can better cardiovascular care close the mortality gap for people with schizophrenia? JAMA Psychiatry 75, 1215–1216.
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1545–1602.
    1. GBD 2017 Causes of Death Collaborators (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736–1788.
    1. GBD 2017 DALYs and HALE Collaborators (2018) Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1859–1922.
    1. GBD 2017 Diet Collaborators (2019) Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 393, 1958–1972.
    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858.
    1. GBD 2017 Mortality Collaborators (2018) Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1684–1735.
    1. GBD 2017 Risk Factor Collaborators (2018) Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1923–1994.
    1. Hadar R, Winter R, Edemann-Callesen H, Wieske F, Habelt B, Khadka N, Felgel-Farnholz V, Barroeta-Hlusicka E, Reis J, Tatarau CA, Funke K, Fritsch B, Bernhardt N, Bikson M, Nitsche MA and Winter C (2019) Prevention of schizophrenia deficits via non-invasive adolescent frontal cortex stimulation in rats. Molecular Psychiatry. . [Epub ahead of print]
    1. Hemager N, Plessen KJ, Thorup A, Christiani C, Ellersgaard D, Spang KS, Burton BK, Gregersen M, Sondergaard A, Greve AN, Gantriis DL, Poulsen G, Seidman LJ, Mors O, Nordentoft M and Jepsen J (2018) Assessment of neurocognitive functions in 7-year-old children at familial high risk for schizophrenia or bipolar disorder: the Danish high risk and resilience study VIA 7. JAMA Psychiatry 75, 844–852.
    1. Hjorthoj C, Sturup AE, McGrath JJ and Nordentoft M (2017) Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. The Lancet. Psychiatry 4, 295–301.
    1. Hollander AC, Dal H, Lewis G, Magnusson C, Kirkbride JB and Dalman C (2016) Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. BMJ 352, i1030.
    1. Isohanni M, Miettunen J, Jaaskelainen E, Moilanen J, Hulkko A and Huhtaniska S (2018) Under-utilized opportunities to optimize medication management in long-term treatment of schizophrenia. World Psychiatry 17, 172–173.
    1. Kirkbride JB, Hameed Y, Ankireddypalli G, Ioannidis K, Crane CM, Nasir M, Kabacs N, Metastasio A, Jenkins O, Espandian A, Spyridi S, Ralevic D, Siddabattuni S, Walden B, Adeoye A, Perez J and Jones PB (2017) The epidemiology of first-episode psychosis in early intervention in psychosis services: findings from the Social Epidemiology of Psychoses in East Anglia [SEPEA] Study. American Journal of Psychiatry 174, 143–153.
    1. Kugathasan P, Horsdal HT, Aagaard J, Jensen SE, Laursen TM and Nielsen RE (2018) Association of secondary preventive cardiovascular treatment after myocardial infarction with mortality among patients with schizophrenia. JAMA Psychiatry 75, 1234–1240.
    1. Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, Jin L, Zhang T and Chen X (2019) The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. Journal of Hepatology 70, 674–683.
    1. Lysaker PH, Pattison ML, Leonhardt BL, Phelps S and Vohs JL (2018) Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry 17, 12–23.
    1. Ma L, Semick SA, Chen Q, Li C, Tao R, Price AJ, Shin JH, Jia Y, Brandon NJ, Cross AJ, Hyde TM, Kleinman JE, Jaffe AE, Weinberger DR and Straub RE (2019) Schizophrenia risk variants influence multiple classes of transcripts of sorting nexin 19 (SNX19). Molecular Psychiatry. . [Epub ahead of print]
    1. Melle I, Olav JJ, Haahr UH, Ten VHW, Joa I, Langeveld J, Larsen TK, Ilner OS, Qin P, Ivar RJ, Rishovd RB, Simonsen E, Vaglum P, McGlashan TH and Friis S (2017) Causes and predictors of premature death in first-episode schizophrenia spectrum disorders. World Psychiatry 16, 217–218.
    1. Riglin L, Collishaw S, Richards A, Thapar AK, Maughan B, O'Donovan MC and Thapar A (2017) Schizophrenia risk alleles and neurodevelopmental outcomes in childhood: a population-based cohort study. The Lancet. Psychiatry 4, 57–62.
    1. Vita A, Barlati S, De Peri L, Deste G and Sacchetti E (2016) Schizophrenia. Lancet 388, 1280.
    1. Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H and Abi-Dargham A (2017) Pathway-specific dopamine abnormalities in schizophrenia. Biological Psychiatry 81, 31–42.
    1. Zhuo C and Triplett PT (2018) Association of schizophrenia with the risk of breast cancer incidence: a meta-analysis. JAMA Psychiatry 75, 363–369.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj